                         SEQUENCE LISTING

<110>  Neurimmune AG
 
<120>  Combination therapy for TTR amyloidosis

<130>  NE30A89/P-WO

<150>  EP 20174177.4
<151>  2020-05-12

<160>  7     

<170>  PatentIn version 3.5

<210>  1
<211>  360
<212>  DNA
<213>  Homo sapiens


<220>
<221>  CDS
<222>  (1)..(360)
<223>  NI-301.37F1 variable heavy chain (VH) sequence

<220>
<221>  V_region
<222>  (91)..(105)
<223>  complementarity determining region (CDR) VH-CDR1

<220>
<221>  V_region
<222>  (154)..(201)
<223>  complementarity determining region (CDR) VH-CDR2

<220>
<221>  V_region
<222>  (298)..(327)
<223>  complementarity determining region (CDR) VH-CDR3

<400>  1
cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gag         48
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu           
1               5                   10                  15                

acc ctg tcc ctc acc tgc agt gtc tct ggt ggc tcc atc atc agt agg         96
Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Ile Ser Arg           
            20                  25                  30                    

agt tcc tac tgg ggc tgg atc cgc cag ccc cca ggg aag ggg ctg gag        144
Ser Ser Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu           
        35                  40                  45                        

tgg att ggg ggt atc tat cat agt ggg aac act tac gac aac ccg tcc        192
Trp Ile Gly Gly Ile Tyr His Ser Gly Asn Thr Tyr Asp Asn Pro Ser           
    50                  55                  60                            

ctc aag agt cga ctc acc atg tcc gta gac acg tcg aag aac cag ttc        240
Leu Lys Ser Arg Leu Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe           
65                  70                  75                  80            

tcc ctg aat ctg agg tct gtg acc gcc gca gac acg gct gtg tat tac        288
Ser Leu Asn Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr           
                85                  90                  95                

tgt gcg agg ata gtg ccg ggg ggt gat gct ttt gat atc tgg ggc caa        336
Cys Ala Arg Ile Val Pro Gly Gly Asp Ala Phe Asp Ile Trp Gly Gln           
            100                 105                 110                   

ggg aca atg gtc acc gtc tct tcg                                        360
Gly Thr Met Val Thr Val Ser Ser                                           
        115                 120                                           


<210>  2
<211>  120
<212>  PRT
<213>  Homo sapiens

<400>  2

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Ile Ser Arg 
            20                  25                  30          


Ser Ser Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Ile Gly Gly Ile Tyr His Ser Gly Asn Thr Tyr Asp Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Leu Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe 
65                  70                  75                  80  


Ser Leu Asn Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Ile Val Pro Gly Gly Asp Ala Phe Asp Ile Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  3
<211>  321
<212>  DNA
<213>  Homo sapiens


<220>
<221>  CDS
<222>  (1)..(321)
<223>  NI-301.37F1 variable K-light chain (VK) sequence

<220>
<221>  V_region
<222>  (70)..(102)
<223>  complementarity determining region (CDR) VK-CDR1

<220>
<221>  V_region
<222>  (148)..(168)
<223>  complementarity determining region (CDR) VK-CDR2

<220>
<221>  V_region
<222>  (265)..(291)
<223>  complementarity determining region (CDR) VK-CDR3

<400>  3
gac atc cag atg acc cag tct cca tcc tcc ctg tct gca tct gta gga         48
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly           
1               5                   10                  15                

gac aga gtc aca atc gct tgc cgg gcc agt cag agc gtt ggc acc tat         96
Asp Arg Val Thr Ile Ala Cys Arg Ala Ser Gln Ser Val Gly Thr Tyr           
            20                  25                  30                    

tta aat tgg tat cag cag aaa aga ggg aaa gcc cct aaa ctc ctc atc        144
Leu Asn Trp Tyr Gln Gln Lys Arg Gly Lys Ala Pro Lys Leu Leu Ile           
        35                  40                  45                        

ttt gct gca tcc agt ttg caa agt ggg gtc cca tca agg ttc agt ggc        192
Phe Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly           
    50                  55                  60                            

agt gga tct ggg aca gat ttc act ctc acc atc agc agt ctg caa cct        240
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro           
65                  70                  75                  80            

gaa gac ttt gca act tac tac tgt caa cag agt tac agt tct cct cca        288
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ser Pro Pro           
                85                  90                  95                

acg ttc ggc caa ggg acc aag gtg gag atc aaa                            321
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys                               
            100                 105                                       


<210>  4
<211>  107
<212>  PRT
<213>  Homo sapiens

<400>  4

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ala Cys Arg Ala Ser Gln Ser Val Gly Thr Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Arg Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Phe Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ser Pro Pro 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  5
<211>  360
<212>  DNA
<213>  Homo sapiens


<220>
<221>  CDS
<222>  (1)..(360)
<223>  NI-301.37F1-PIMC variable heavy chain (VH) sequence after 
       correction of primer induced mutations

<220>
<221>  V_region
<222>  (91)..(105)
<223>  complementarity determining region (CDR) VH-CDR1

<220>
<221>  V_region
<222>  (154)..(201)
<223>  complementarity determining region (CDR) VH-CDR2

<220>
<221>  V_region
<222>  (298)..(327)
<223>  complementarity determining region (CDR) VH-CDR3

<400>  5
cag ctg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gag         48
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu           
1               5                   10                  15                

acc ctg tcc ctc acc tgc agt gtc tct ggt ggc tcc atc atc agt agg         96
Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Ile Ser Arg           
            20                  25                  30                    

agt tcc tac tgg ggc tgg atc cgc cag ccc cca ggg aag ggg ctg gag        144
Ser Ser Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu           
        35                  40                  45                        

tgg att ggg ggt atc tat cat agt ggg aac act tac gac aac ccg tcc        192
Trp Ile Gly Gly Ile Tyr His Ser Gly Asn Thr Tyr Asp Asn Pro Ser           
    50                  55                  60                            

ctc aag agt cga ctc acc atg tcc gta gac acg tcg aag aac cag ttc        240
Leu Lys Ser Arg Leu Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe           
65                  70                  75                  80            

tcc ctg aat ctg agg tct gtg acc gcc gca gac acg gct gtg tat tac        288
Ser Leu Asn Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr           
                85                  90                  95                

tgt gcg agg ata gtg ccg ggg ggt gat gct ttt gat atc tgg ggc caa        336
Cys Ala Arg Ile Val Pro Gly Gly Asp Ala Phe Asp Ile Trp Gly Gln           
            100                 105                 110                   

ggg aca atg gtc acc gtc tct tcg                                        360
Gly Thr Met Val Thr Val Ser Ser                                           
        115                 120                                           


<210>  6
<211>  120
<212>  PRT
<213>  Homo sapiens

<400>  6

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Ile Ser Arg 
            20                  25                  30          


Ser Ser Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Ile Gly Gly Ile Tyr His Ser Gly Asn Thr Tyr Asp Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Leu Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe 
65                  70                  75                  80  


Ser Leu Asn Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Ile Val Pro Gly Gly Asp Ala Phe Asp Ile Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  7
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Epitope recognized by NI-301.37F1 antibody


<220>
<221>  PEPTIDE
<222>  (1)..(5)
<223>  Epitope of NI-301.37F1 antibody, aa 41 to aa 45

<400>  7

Trp Glu Pro Phe Ala 
1               5   


